In tandem with Enhertu’s inclusion in China’s national insurance program, Daiichi Sankyo is planting a foothold in local ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Toshinori Agatsuma, head of research at Daiichi Sankyo, has died. He led development of ADC technology behind breast cancer ...

Daiichi Sankyo Company is making significant strides in the pharmaceutical industry, evidenced by its financial growth and strategic collaborations, such as with Merck on MK-6070. The company is set ...

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

Breast Cancer Foundation NZ and the Breast Cancer Aotearoa Coalition are overjoyed Kiwis with an aggressive form of incurable breast cancer will be able to access a game-changing new drug in the new ...

The government's drug funding agency Pharmac is asking for public feedback on its proposal to fund four new medicines for ...

A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be ...